ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

Google News - UAE — 30 Jul 02:45 GST · 5 sources

Read the full story at Google News - UAE →

Also covering this story

Google News - UAE: ImmunityBio stock jumps on UAE drug approval for ANKTIVA By Investing.com
Google News - UAE: Patrick Soon-Shiong: So Excited That UAE EDE Took the Lead to Authorize the Broadest Aproval for ANKTIVA
Google News - UAE: The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval - Learn Why
Google News - UAE: ImmunityBio stock jumps on UAE drug approval for ANKTIVA By Investing.com

← Back to UAEMeme